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How the immune system is negatively affected by sepsis is not fully understood. In this issue of Immunity,
Shalova et al. (2015) show that during human sepsis monocytes upregulate hypoxia-inducible factor-a
(HIF1-a) activity and acquire an immunosuppressive phenotype while retaining anti-bacterial and wound-
healing properties.Inflammation is a good thing. It removes
infections and paves the way for tissue
repair and the re-establishment of ho-
meostasis. It’s a delicate balance be-
tween pro- and anti-inflammatory signals
followed by a sequence of pro-resolution
events. However, inflammation can also
be a very bad thing. During sepsis, for
instance, an overexuberant and pro-
longed activation of the innate immune
system results in a ‘‘cytokine storm’’
causing physiological shock and multiple
organ failure. That notwithstanding, phar-
macological interventions aimed at quel-
ling these unbridled drivers of the innate
response have proven largely ineffective
in treating the critically ill. Instead, a pre-
dominantly anti-inflammatory period—
the compensatory anti-inflammatory
response syndrome (CARS)—is now re-
garded as the primary clinical concern.
This phase is associated with microcircu-
latory dysfunction, coagulopathy, cata-
bolic predominance, and bioenergetic
failure leading to multi-organ failure (Full-
erton and Singer, 2011). However, it is
principally marked by vulnerability to hos-
pital-acquired infection and repeated
episodes of sepsis. Indeed, the immune
component of CARS, described as immu-
noparalysis, anergy, or leukocyte re-pro-
gramming, (Hotchkiss et al., 2009) might
pose an equal if not a greater threat to
the host than the initial ‘‘cytokine storm.’’
The proposed mechanisms involved are
complex. Loss of key effector cells espe-
cially via apoptosis, a shift in cytokines
from a pro-inflammatory to an anti-inflam-
matory profile, alteration in cell-surface
receptor expression, and multiple other
alterations have been reported. Impor-
tantly, gene-expression profiling of the in-flammatory response in the critically ill has
demonstrated that although there is vari-
ability between different initiating stimuli
(Tang et al., 2010), a consistent picture
emerges regardless of etiology (Xiao
et al., 2011) or pathogen (Tang et al.,
2008). This indicates that a fundamental
human transcriptomic response to severe
inflammatory stress might exist across all
forms of sepsis. Thus, these data indicate
that the etiology of the innate immune
response during sepsis episodes might
not be as heterogeneous as previously
suspected. This renders the regulation of
inflammation an appealing therapeutic
target in the critically ill. In this issue of
Immunity, Shalova et al. (2015) have
examined the impact of Gram negative-
induced sepsis on monocyte-effector
function. The overall aim is understand
how a severe inflammatory insult nega-
tively affects the innate immune system
leading, in turn, to the poor clinical
outcome that is typically associated with
sepsis. These authors found that the
phenotype of monocytes taken from
patients within a few hours of infection
shifted from a pro-inflammatory to
an immune-suppressive phenotype in
monocytes taken from patients who
recovered. It is proposed that elevated
hypoxia-inducible factor-a (HIF1-a) trig-
gers IRAKM, a negative modulator of
TLR signaling, leading to an endotoxin-
tolerant monocyte that interestingly also
acquires anti-bacterial and wound-heal-
ing properties.
Sepsis is a complex response to injury
and infection, and trying to understand
its regulatory pathways is no trivial under-
taking. The pathogenesis that underpins
its impact on organ dysfunction and itsImmunity 4subsequent immune suppression pre-
disposing to nosocomial infection, not
the mention its dire long-term mortality,
cannot be ascribed to one single cell,
soluble mediator, receptor, or signaling
factor. Nonetheless, in an attempt to un-
derstand the role of at least one of the
key protagonists within the pantheon of
sepsis, Shalova et al. carried out tran-
scriptomic analysis on circulating mono-
cyte populations from patients with active
sepsis (within a few hours of a defined
gram-negative infection) and compared
this phenotype to monocytes from the
same patients 4–12 weeks later, in which
they termed ‘‘recovery phase.’’ In cells
taken from patients with active sepsis
the usual pro-inflammatory suspects (nu-
clear factor-kB [NF-kB], interleukin-6 [IL-
6], IL-1b, and chemokines CCL3, CCL5)
emerged alongside elevated IL-10 and
cell surface markers of immune dysfunc-
tion. As expected, a different picture was
painted by monocytes taken from those
patients who recovered from sepsis being
more akin to the transcriptome of mono-
cytes from healthy volunteers. Thereafter,
a comparative transcriptomic profile of
these respective monocyte populations
was obtained after their stimulation with
LPS ex vivo. ‘‘Recovery monocytes’’ dis-
played a range of cytokines and chemo-
kines whereas ‘‘sepsis monocytes’’ were
largely refractory to LPS in this regard.
Moreover, sepsis monocytes displayed
apparent reduced antigen presentation
and downregulation of major histocom-
patibility complex-II (MHC-II) genes and
co-stimulatory molecules; the hallmarks
of cells experiencing endotoxin tolerance.
The authors proposed that elevated
HIF1-a and subsequent upregulation of2, March 17, 2015 ª2015 Elsevier Inc. 397
Figure 1. Sepsis-Conditioned Monocyte Plasticity
As a consequence of a Gram-negative bacteria-induced sepsis in adult humans, monocytes upregulate
HIF1-a that, in turn, mediates functional reprograming of monocytes. These monocytes acquire an immu-
nosuppressive phenotype compared to monocytes from healthy volunteers or monocytes from patients
who have recovered from sepsis stimulated with endotoxin in vitro. It is proposed that HIF1a acts as a
regulator of IRAKM, a negative modulator of TLR signaling, leading to an endotoxin-tolerant monocyte.
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IRAKM, mediated this immune anergy
in sepsis circulating monocytes, see
Figure 1. However, one must be careful
not to over-interpret these findings as
complete immune paralysis, because the
authors also observed an elevation in
genes associated with metabolism and
phagocytosis in sepsis monocytes stimu-
lated with LPS compared to recovery
monocytes. For instance, monocytes
from patients experiencing sepsis ex-
hibited apparent increased bacterial
phagocytosis and increased expression
of the antimicrobial peptide HAMP.
Moreover, despite expressing matrix
metallopeptidase 9 (MMP9), MMP19,
and vascular endothelial growth factor
(VEGF), sepsis monocytes stimulated re-
epithelialization of wounded fibroblasts
in an ex vivo assay of wound healing
compared to monocytes from patients
who survived sepsis. These findings belie
the notion that monocytes from the height
of sepsis lack host defense capabilities.
Rather, it suggests a form of ‘‘homeo-
static-to-inflammation’’ reprogramming,
a type of reconfiguration commensurate
with its inflammatory environment rather
than global suppression.
Shalova et al. shed light on the tran-
scriptome of circulating monocytes taken
from humans with sepsis and identified398 Immunity 42, March 17, 2015 ª2015 Elsethe HIF1a-IRAKM axis as a potential
culprit in mediating endotoxin tolerance;
a factor that might be responsible for
the long term clinical sequelae typical
of sepsis. These experiments used con-
ventional adherence assays to isolate
monocytes for analysis. Circulating
monocytes in the healthy adult are
composed of classical monocytes
(CD14hiCD16), double-positive mono-
cytes (CD14+CD16+), and non-classical
monocytes (CD14dimCD16hi) (Ziegler-
Heitbrock et al., 2010), with distinct
monocyte subsets most likely undertak-
ing different effector functions during
pathology. A number of studies have
demonstrated that the natural equilibrium
of these subsets is altered during chronic
and acute inflammation including sepsis,
liver fibrosis, and rheumatoid arthritis
favoring increased CD14+CD16+ cells.
Whether this is a bona fide quantitative in-
crease in these inflammatory monocytes
or simply a sequestration of classical
monocytes thereby altering the relative
ratio of these cells to one another remains
to be verified. Moreover, it’s not known
whether this ratio reverts back to that
experienced during steady state when
inflammation resolves. Therefore, the
transcriptome signature reported by Sha-
lova and colleagues unlocks new avenues
for monocyte research during sepsis.vier Inc.However, the septic phenotype reported
needs to be ascribed to a particular
monocyte subset or subsets. This would
also inform on putative sepsis-induced
shifts in monocyte populations during
and after sepsis; an undoubtedly invalu-
able piece of information.
In summary, Shalova et al. have taken
the bold step of trying to understand the
phenotype of monocyte during sepsis
with a view of developing better manage-
ment protocols and novel treatment
regimen for sepsis patients; an area of
medicine that has experienced consider-
able pharmacological failure. An explana-
tion for this failure is frustratingly unclear,
particularly given that a fundamental hu-
man transcriptomic response to severe
inflammatory stress (Xiao et al., 2011)
might exist across all forms of sepsis
and now between human and rodents
(Seok et al., 2013; Shay et al., 2015; Takao
and Miyakawa, 2015). Certainly, there
are many differences between rodents
and humans, including ratios of peripheral
blood leukocyte populations, while hu-
mans might have comorbidities and
be prescribed complex drug cocktails.
Moreover, with rodents, tissues can be
sampled at specific time points after
defined stimulation, whereas samples
from humans are most likely derived
from patients at various stages of disease
progression driven by a less well-defined
stimulus. Armed with data from Shalova
et al., the next step should be a transcrip-
tomic analysis on monocyte subsets and
other innate cells including the indispens-
able neutrophil, from controlled individ-
uals before, during and after experimen-
tally-induced endotoxemia. Aligning this
transcriptomic profile with clinical signs
of disease status might provide a window
of drug intervention that would have being
otherwise obscured by the asynchronous
nature of sepsis in the human population.
This will provide a treatment regime
aimed at targeting pathogenic effector
molecules as well as biochemical and
molecular pathways that drive sepsis
and in particular those responsible for
CARS. Results from these experiments
might also inform on the abysmal long-
term survival rates of patients who experi-
ence severe sepsis (5-year mortality rate
of >70%). These studies will surely deter-
mine how these signatures could be
harnessed to ensure a more positive
outcome of systemic inflammation.
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Effector CD8+ T cells scan tissues to locate and kill infected host cells. In this issue of Immunity, Hickman
et al. (2015) show that the exploration is not random: infected monocytes attract their assassins by secreting
chemokines, which accelerates clearance of epicutaneous vaccinia virus infection.During viral infections, effector CD8+
T cells patrol sites of inflammation and
scan host cells for evidence of infection.
Virally infected cells announce their in-
fected state to these effector CD8+ T cells
by presenting pathogen-derived peptides
on their surface major histocompatibility
complex (MHC) class I molecules, and
this requires contact between both cells.
Recognition by CD8+ T cells triggers elimi-
nation of the infected host cell, which takes
the virus down with it. The amazing thing
about this process is the vast number of
host cells that might need to be surveyed.
How do CD8+ T cells find infected targets
among millions of host cells? A number of
observed behaviors might increase the ef-
ficiency of this process. In cell-dense com-
partments, such as the epidermis, CD8+
T cells can adopt dendritic morphologies
to increase the number of cell contacts
(Ariotti et al., 2012). Effector T cells are
highlymotile withinmany infected nonlym-
phoid tissues (Mueller, 2013). Expression
of the inflammatory chemokine CXCL10,
which is one of two CXCR3 ligands in
C57BL/6 mice (CXCL9 is the other), hasalso been shown to increase the rate of
effector CD8+ T cell motility in the brain
during chronic Toxoplasma gondii infec-
tion (Harris et al., 2012). In this study,
effector CD8+ T cells have been shown
to exhibit specialized migration patterns
knownasLe`vywalks,which arecharacter-
ized by short steps within a small area and
occasional longer runs. Le`vy walks have
been proposed to increase the foraging
efficiency of marine predators, insects,
and human hunter-gatherers when food is
sparse (Raichlen et al., 2014; Viswanathan
et al., 1999). Le`vy walk behavior, although
still fundamentally random, is believed
to allow CD8+ T cells to find rare infected
targets with more than an order of magni-
tude more efficiency than random Brow-
nian motion walks (Harris et al., 2012). A
critical question is whether CD8+ T cells
searching within nonlymphoid sites of
infection are limited to random migration
behavior or whether they might also be
specifically directed toward infected cells
in some contexts.
Hickman et al. explored this question
after epicutaneously infecting mice withvaccinia virus, which replicates in both
epidermal keratinocytes and dermal in-
flammatory monocytes (Hickman et al.,
2013). They previously reported that
Ly6G+ innate immune cells are impor-
tant for clearance of virus from keratino-
cytic foci, whereas infected inflammatory
monocytes are targeted principally by
CD8+ T cells (Hickman et al., 2013). In
the current study, they investigated the
hypothesis that effector CD8+ T cells
within the dermis migrate toward chemo-
kine-mediated cries for help emanating
from infected cells.
After vaccinia virus infection, CD8+
T cells became activated and migrated to
the infected ear. Transcriptional profiling
revealed that compared to uninfected
controls, infected inflammatory mono-
cytes showed upregulation of chemokines
CXCL9 and CXCL10. The chemokine re-
ceptor CXCR3 is expressed on subsets
of effector and memory CD8+ T cells and
has been implicated in T cell priming,
effector differentiation, and migration.
Hickmanet al. found that CXCR3-deficient
mice exhibited a greater number of2, March 17, 2015 ª2015 Elsevier Inc. 399
